Polymyxin B Dosing in Renal Impairment (CrCL 20-30 mL/min)
For a 70-kg adult with creatinine clearance of 20-30 mL/min, administer polymyxin B as a loading dose of 150-175 mg (1.5-2.5 million units), followed by a maintenance dose of 50-60 mg (500,000-600,000 units) every 12 hours.
Dose Conversion Reference
Before discussing specific dosing, understand the critical conversion: 1 mg polymyxin B sulfate = 10,000 units 1. This means:
- 150 mg = 1.5 million units
- 100 mg = 1 million units
- 50 mg = 500,000 units
Loading Dose
Administer 150-175 mg (1.5-1.75 million units) as a loading dose, which translates to approximately 2.5 mg/kg for a 70-kg patient 2, 3. This loading dose should be given regardless of renal function, as it is necessary to rapidly achieve therapeutic concentrations 4.
Maintenance Dosing in Renal Impairment
For CrCL 20-30 mL/min, the maintenance dose should be reduced from standard dosing:
- Recommended: 50-60 mg (500,000-600,000 units) every 12 hours 5, 6
- This represents approximately 100-120 mg total daily dose
Rationale for Dose Reduction
The evidence strongly supports dose reduction in renal impairment:
Recent population pharmacokinetic studies demonstrate that creatinine clearance significantly affects polymyxin B clearance 7, 4. Patients with CrCL <40 mL/min have reduced drug clearance and require lower maintenance doses to avoid toxicity while maintaining efficacy.
A 2021 Chinese study specifically showed that 60 mg every 12 hours in patients with renal impairment (mean CrCL 42 mL/min) achieved ≥90% probability of target attainment against organisms with MIC ≤2 mg/L, with acceptable toxicity risk 5.
Real-world data from Chinese patients with renal impairment receiving 50 mg every 12 hours (100 mg/day) successfully controlled infections, though 4 of 5 patients required CRRT during treatment 6.
Critical Caveats
Contradictory FDA Labeling
The FDA label recommends 15,000-25,000 units/kg/day (150-250 mg/day for 70 kg) with reduction for renal impairment 1. However, this recommendation conflicts with modern pharmacokinetic evidence showing poor correlation between creatinine clearance and polymyxin B clearance when using weight-based dosing 8.
Fixed vs. Weight-Based Dosing
Recent evidence favors fixed-dose maintenance regimens over weight-based dosing in renal impairment 3, 4:
- Fixed dosing of 60-75 mg every 12 hours provides more predictable exposure
- Weight-based dosing may lead to excessive exposure and nephrotoxicity in patients with impaired renal function
- For your 70-kg patient with CrCL 20-30 mL/min, a fixed dose of 60 mg every 12 hours balances efficacy and safety
Therapeutic Drug Monitoring
Strongly consider therapeutic drug monitoring (TDM) if available 9, 4. Target steady-state AUC of 50-100 mg·h/L. TDM is particularly important in renal impairment due to:
- High interindividual variability in clearance
- Narrow therapeutic window
- Risk of nephrotoxicity with excessive exposure
Combination Therapy
Polymyxin B should be used in combination therapy, not as monotherapy 9. Consider combining with:
- Meropenem (extended infusion if MIC ≤8 mg/L)
- Tigecycline
- Other agents based on susceptibility testing
Monitoring Requirements
During treatment, monitor:
- Renal function closely - expect potential worsening requiring CRRT 6
- Serum creatinine and urine output daily
- Neurotoxicity signs (muscle weakness, cognitive changes) 6
- Avoid concurrent nephrotoxic or ototoxic drugs 9
Practical Dosing Algorithm
- Day 1: Give loading dose of 150 mg (1.5 million units) IV over 60-90 minutes
- Day 1 onwards: Give maintenance dose of 60 mg (600,000 units) IV every 12 hours
- If TDM available: Adjust dose to achieve AUC 50-100 mg·h/L
- If infection severe or MIC ≥2 mg/L: Consider 75 mg every 12 hours, but monitor closely for toxicity
- If renal function worsens: Do NOT further reduce dose initially; instead, optimize with TDM or consider CRRT 4